The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Table 2 The changes of serologic markers at three clinical situations in HPD, SD, and PR/CR groups (n = 155)^a

Serologic marker		HPD	SD	PR/CR	P value
Serologic marker		(n = 26)	(n = 79)	(n = 50)	P value
At the beginning of prior treatment
NLR	< 5 vs. ≥ 5	17:9	58:21	39:11	0.341
PLR	< 150 vs. ≥ 150	8:18	33:46	16:34	0.835
CAR	< 0.5 vs. ≥ 0.5	12:14	63:16	40:10	0.004
LDH	< 400 vs. ≥ 400	9:17	30:49	17:33	0.706
At the beginning of immunotherapy
NLR	< 5 vs. ≥ 5	17:9	65:14	39:11	0.203
PLR	< 150 vs. ≥ 150	8:18	33:46	22:28	0.265
CAR	< 0.5 vs. ≥ 0.5	10:16	57:22	32:18	0.026
LDH	< 400 vs. ≥ 400	10:16	26:53	18:32	0.581
At 1st tumor response assessment (6–8 weeks after initiation of ICBs)
NLR	< 5 vs. ≥ 5	8:18	71:8	45:5	0.000
PLR	< 150 vs. ≥ 150	7:19	42:37	29:21	0.004
CAR	< 0.5 vs. ≥ 0.5	9:17	56:23	32:18	0.001
LDH	< 400 vs. ≥ 400	4:22	24:55	19:31	0.043

^a Non-evaluable group and Non-HPD PD group were excluded
CAR C-reactive protein-albumin ratio, ICB immune checkpoint blockades, LDH lactate dehydrogenase, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio

ISSN: 1471-2407